Literature DB >> 30660536

Natural History of Functional Tricuspid Regurgitation: Implications of Quantitative Doppler Assessment.

Philipp E Bartko1, Henrike Arfsten1, Maria K Frey1, Gregor Heitzinger1, Noemi Pavo1, Anna Cho1, Stephanie Neuhold2, Timothy C Tan3, Guido Strunk4, Christian Hengstenberg1, Martin Hülsmann1, Georg Goliasch5.   

Abstract

OBJECTIVES: This study sought to define the relationship between functional tricuspid regurgitation (TR) and mortality in patients with heart failure with reduced ejection fraction (HFrEF); and to establish the prognostic value of quantitative measures of TR severity (i.e., effective regurgitant orifice area [EROA] and regurgitant volume).
BACKGROUND: The significance of TR in chronic heart failure is controversial. Earlier studies have shown an independent impact of TR on mortality, whereas more recent evidence suggests myocardial impairment to be the driving force of mortality rather than TR itself. Earlier studies have used qualitative measures of TR severity, hence the prognostic value of more quantitative measures of TR severity (i.e., EROA and regurgitant volumes) remains unclear.
METHODS: We enrolled 382 patients with HFrEF on guideline-directed medical therapy and assessed TR EROA and regurgitant volume by Doppler/2-dimensional echocardiography. All-cause mortality was defined as the primary study endpoint.
RESULTS: TR severity was associated with the HFrEF phenotype with more symptoms (p = 0.004), higher neurohumoral activation (p < 0.001), progressive right-ventricular dilatation (p < 0.001), and impaired function (p < 0.001). Cox regression showed a strong association between quantitative measures of TR with mortality (all p < 0.001). Quantitative metrics of TR severity were consistently associated with mortality with a hazard ratio of 1.009 (95% confidence interval: 1.004 to 1.013; p < 0.001) per 0.01 cm2 increase of the EROA and of 1.013 (95% confidence interval: 1.007 to 1.020; p < 0.001) per 1-ml increase in regurgitant volume. Results remained unchanged after bootstrap- or clinical confounder-based adjustment. A spline curve pattern illustrates the association with mortality with thresholds for the EROA ≥0.2 cm2, and the regurgitant volume ≥20 ml with sustained excess mortality thereafter.
CONCLUSIONS: This large-scale outcome study demonstrates the prognostic value of quantitative Doppler-echocardiographic measures of TR severity in HFrEF. The thresholds for EROA and TR regurgitant volume associated with mortality in our study fall within current ranges defining nonsevere TR. This may potentially impact therapeutic decision making, particularly timing of intervention.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  effective regurgitant orifice area; heart failure with reduced ejection fraction; regurgitant volume; tricuspid regurgitation; vena contracta width

Year:  2019        PMID: 30660536     DOI: 10.1016/j.jcmg.2018.11.021

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  11 in total

1.  Added value of transthoracic 2D echocardiographic en face view of the tricuspid valve.

Authors:  Matthias Schneider; Thomas Binder
Journal:  Wien Klin Wochenschr       Date:  2020-01-13       Impact factor: 1.704

2.  Interventional treatment of tricuspid regurgitation : An important innovation in cardiology.

Authors:  Georg Goliasch; Julia Mascherbauer
Journal:  Wien Klin Wochenschr       Date:  2020-02       Impact factor: 1.704

3.  Anatomic Description of Tricuspid Apparatus Interference From Implantable Intracardiac Devices.

Authors:  Michael Henry; AbdulRahman Abutaleb; Valluvan Jeevanandam; Heather Smith; Mark Belkin; Aliya Husain; Sean Pinney; Takeyoshi Ota; Roberto M Lang; Karima Addetia
Journal:  JACC Cardiovasc Imaging       Date:  2021-02-10

4.  Right ventricle dysfunction assessment for transcatheter tricuspid valve repair: A matter of debate.

Authors:  Alberto Preda; Francesco Melillo; Luca Liberale; Fabrizio Montecucco; Eustachio Agricola
Journal:  Eur J Clin Invest       Date:  2021-07-26       Impact factor: 5.722

Review 5.  Imaging and Patient Selection for Transcatheter Tricuspid Valve Interventions.

Authors:  Mirjam G Winkel; Nicolas Brugger; Omar K Khalique; Christoph Gräni; Adrian Huber; Thomas Pilgrim; Michael Billinger; Stephan Windecker; Rebecca T Hahn; Fabien Praz
Journal:  Front Cardiovasc Med       Date:  2020-05-05

6.  PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation: a propensity-matched analysis.

Authors:  Atsushi Sugiura; Johanna Vogelhuber; Can Öztürk; Zita Schwaibold; David Reckers; Tadahiro Goto; Refik Kavsur; Marc Ulrich Becher; Sebastian Zimmer; Georg Nickenig; Marcel Weber
Journal:  Clin Res Cardiol       Date:  2020-12-12       Impact factor: 5.460

7.  Prognostic Value of Echocardiographic Right Ventricular Function Parameters in the Presence of Severe Tricuspid Regurgitation.

Authors:  Matthias Schneider; Varius Dannenberg; Andreas König; Welf Geller; Thomas Binder; Christian Hengstenberg; Georg Goliasch
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

8.  Case Report: Assessing the Position of Pacemaker Leads via Transthoracic Echocardiography: Additional Value of the Subcostal En Face View.

Authors:  Andrea Simone Deichl; Philipp Lacour; Evgeny Belyavskiy; Burkert Pieske; Elisabeth Pieske-Kraigher; Florian Blaschke; Matthias Schneider
Journal:  Front Cardiovasc Med       Date:  2021-06-04

9.  An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation.

Authors:  Georg Spinka; Philipp E Bartko; Gregor Heitzinger; Eliza Teo; Suriya Prausmüller; Henrike Arfsten; Noemi Pavo; Max-Paul Winter; Julia Mascherbauer; Christian Hengstenberg; Martin Hülsmann; Georg Goliasch
Journal:  J Pers Med       Date:  2020-11-16

Review 10.  Functional tricuspid regurgitation, related right heart remodeling, and available treatment options: good news for patients with heart failure?

Authors:  Marijana Tadic; Cesare Cuspidi; Daniel Armando Morris; Wolfang Rottbauer
Journal:  Heart Fail Rev       Date:  2021-07-15       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.